Gene Editing Stocks Rise as Trial Data and FDA Draft Framework Draw Attention

Early clinical findings and a proposed FDA framework for individualized genome editing helped lift several gene therapy stocks during the week. The clearest clinical signal came from Beam Therapeutics’ small Phase I/II study of BEAM-301. The FDA proposal, meanwhile, could give developers a way to adapt a treatment for different genetic variants within one application. Both developments drew investor interest, but neither settles how well these therapies will work or how broadly the proposed framework might apply.

The European Society of Gene and Cell Therapy’s 33rd annual congress in Hamburg, which ended Friday, brought a series of presentations from therapy developers. Another catalyst arrived October 27, when the FDA issued draft guidance for individualized human genome editing products intended for rare genetic diseases. The agency is accepting comments through November 27, online or by mail.

The draft document describes considerations for submitting and managing Biologics License Applications for individualized genome editing products. Acting FDA commissioner Kyle Diamantas said the proposal recognizes that a single treatment approach may not suit people with rare genetic diseases, and that oversight should account for this variation.

A proposed framework for tailored gene editing

A central concept in the draft is the “Individualized Feature Space,” or IFS. It would set in advance the permitted range of variation in components of an individualized genome editing product. Within those boundaries, a therapy could be adapted from one patient to another while remaining within the scope of a single application, without requiring a separate clinical trial for every permitted variation.

The FDA gives the example of a product whose only changing component is the guide RNA spacer sequence, which helps direct an editing system to a target. An application could specify which spacer sequences are allowed—for instance, sequences aimed at a defined group of disease-causing variants in one gene that produce the same editing result, such as restoring the gene’s instructions for a normal protein.

That approach could matter for conditions caused by many variants in the same gene. Developers may be able to build on evidence for a shared editing strategy instead of starting a wholly separate development program for each genetic change. The practical reach of the proposal will depend on the boundaries defined in each application and on the FDA’s review of the evidence. The document is a draft, so its details may change after comments and review.

Jefferies analyst Maury Raycroft described the proposal as a positive development for gene editing companies, which he said had lagged over the prior year. In his view, upcoming clinical data and other development milestones, alongside a more constructive regulatory climate, could support investor interest. That is an assessment of market prospects, not evidence that a therapy is effective or that an application will succeed.

Prime Medicine and Beam lead weekly gains

Four gene editing developers rose between 4% and 29% over the week. The gains came despite a nearly 3% Friday decline in the Nasdaq Composite after disappointing results from technology and artificial intelligence companies weighed on the wider market.

Prime Medicine had the largest weekly increase. Its shares advanced 29%, from $3.67 on October 23 to $4.72 on Friday. They briefly reached $5.91 on Thursday morning, still below the company’s 52-week high. The move extended a month-long 53% rise following two clinical developments.

Last month, the FDA cleared Prime to begin a planned Phase I/II trial of PM647, an in vivo prime editing candidate for alpha-1 antitrypsin deficiency. In vivo treatments are designed to deliver the editing system into the body, rather than editing cells outside the body and then returning them.

Prime also dosed the first participant on October 5 in a Phase I/II open-label trial of PM577a for Wilson disease caused by the H1069Q mutation. The study includes adults and teenagers. Prime described this as the first reported use of prime editing to alter DNA directly in a person. Initial trial data are expected in 2027, so the first dose marks an early development step rather than proof of benefit.

J.P. Morgan analyst Tessa Romero wrote in June that the company’s pipeline had long-term promise, while tying a more positive view of the shares to future milestones, including initial clinical data in 2027. Raycroft said the proposed FDA framework could also help Prime develop additional mutation-specific editors using much of the existing H1069Q development package. He expects later editors may still need their own work on unintended edits and some clinical evidence.

Beam Therapeutics gained 13%, from $24.05 on October 23 to $27.23 on Friday. Investors responded in part to initial results from its Phase I/II BEAM-301 study in glycogen storage disease type Ia, or GSDIa. The candidate uses base editing reagents delivered to the liver in lipid nanoparticles, with the aim of correcting the R83C mutation, which is linked to a severe form of the disease.

Small study shows a mixed response

At the August 17 data cutoff, two of the three participants in the 40 mg cohort completed the trial’s maximum controlled fasting period of 15 hours. Beam said the result was consistent with restored production of glucose by the body. Both participants also had a reported 100% reduction in daily starch requirements and no longer needed starch supplementation. Their blood glucose control improved, with more time in the normal range and less time at elevated levels.

These findings are encouraging but come from only two people who reached the maximum fasting duration. The third participant in the same cohort did not show an increase in time to fasting hypoglycemia, a measure related to how long a person can go without developing low blood sugar. Beam suggested that body mass index and having one copy of the R83C variant may have contributed. The company has begun enrolling a 60 mg cohort and plans to discuss a possible development path with the FDA.

William Blair analyst Myles Minter called the first clinical look impressive and estimated that BEAM-301 could reach peak yearly sales of $475 million. That forecast is a commercial estimate, not a clinical finding. It is 31% higher than the $362 million peak estimate his colleague Sami Corwin made for Genglycos, the first treatment authorized for GSDIa in adults and children aged eight and older. Ultragenyx Pharmaceutical markets Genglycos.

Raycroft also said the FDA proposal could support Beam’s phenylketonuria program, which he expects could enter clinical testing in late 2026 or early 2027 by drawing on data from three mutation-specific base editors. The proposal’s effect on any particular program remains subject to the FDA’s assessment of the product and its evidence.

Conference findings and upcoming readouts

Editas Medicine rose 11%, from $2.40 on October 23 to $2.67 on Friday. At the Hamburg congress, the company presented work on a configurable manufacturing platform for targeted lipid nanoparticles. The poster described a process designed to evaluate different targeting binders and therapeutic cargo while maintaining consistent product quality across scales, binders and batches. This is manufacturing and platform evidence; it does not establish that a treatment made with the platform benefits patients.

A second Editas poster described delivery of messenger RNA to targeted T cells using the company’s platform. The researchers reported temporary production of a CAR protein in those cells, followed by substantial depletion of B cells in blood within 24 hours. They also reported relevant B-cell depletion in lymphoid tissues and suggested the approach might support immune reset for autoimmune disease. These are early research findings, and the presentation does not demonstrate a clinical effect in people with autoimmune conditions.

Intellia Therapeutics shares gained 11%, from $11.21 to $12.47. Investors are awaiting results for lonvoguran ziclumeran, or Lonvo-z, a one-time CRISPR/Cas9 editing therapy being developed for hereditary angioedema. The company plans to present results at the American College of Allergy, Asthma & Immunology annual meeting in Phoenix, November 12–16. The scheduled presentations include four-year follow-up from participants who received one 50 mg dose. Intellia executives and specialists in the condition also plan a November 12 discussion with analysts about preparations for a possible commercial launch.

CRISPR Therapeutics rose 4%, from $49.39 to $51.42. The company is awaiting a planned update from a Phase Ib study of CTX310, an in vivo CRISPR/Cas9 candidate targeting ANGPTL3 in people with severe hypertriglyceridemia. The presentation is scheduled for the American Heart Association Scientific Sessions, November 6–9. Investors are also awaiting the company’s third-quarter results, which the source article said were due later that month.

Caribou Biosciences moved in the opposite direction, falling nearly 21% over the week, from 53 cents to 42 cents. The company is reviewing strategic options and plans to reduce a substantial portion of its workforce. Its shares had fallen 66% over the preceding month. Those company-level developments, rather than the conference findings or FDA proposal, continued to weigh on the stock.

Drug development work involving artificial intelligence

The source article also described Anthropic’s work in drug development, including an acquisition and six research collaborations. This material is separate from the gene editing stock moves, but illustrates how artificial intelligence companies are testing tools across drug research. Anthropic said it acquired Mithril Medicine in August. Mithril, founded by Cody Tranbarger, was developing treatments for two rare forms of muscular dystrophy with a one-person staff. Tranbarger used Claude to coordinate contracts, logistics and experiments with 11 outside laboratories, among other tasks.

Anthropic said that, within 18 months, Mithril had taken a candidate for one form of muscular dystrophy from an idea to positive results in mice. It projected that, if further work supports the candidates, a treatment could be ready to enter human studies as soon as late 2028. Mouse results do not predict with certainty whether a treatment will prove safe or effective in people.

Anthropic named six research partners: Bristol Myers Squibb and Generate: Biomedicines, both publicly traded, plus private companies BigHat Biosciences, Divergence Labs, Enveda and The Column Group. The examples described by the companies range from analysis and document review to early laboratory designs. Most are preliminary and should not be read as evidence of a treatment’s clinical value.

• Bristol Myers Squibb: The company used Claude language models to estimate the chance of success for planned clinical studies of an unnamed early-stage drug. Anthropic said the partners intend to extend this work in 2027 to examine whether it can help improve the odds of success in early development.
• Generate: Biomedicines: Six scientists used Claude Code to suggest changes to part of the genetic instructions for a CAR T-cell therapy. One design, about 70% shorter than the standard version, performed better in laboratory tests. Generate said more compact intracellular domains could potentially reduce the dose needed to make CAR T cells in the body and leave room for more complex designs. These results are laboratory findings, not patient outcomes.
• BigHat Biosciences: Researchers used Claude to help improve binding, stability and resistance to clumping in two antibody fragments being explored for future medicines. One was designed to recognize cancer cells; the other was designed to help a medicine remain in the body longer. The fragments are potential components, not finished therapies.
• Enveda: The company said connecting manufacturing documents to Claude cut human review time by 89%, from more than 25 hours to under three. After reviewing 1,061 pages, Claude identified all 11 issues found by human reviewers and flagged seven additional issues. This reports a document-review task; it does not show that the system can replace expert review across drug development.
• The Column Group: Its spinout Pleiades plans to use Claude to reduce scientific, operational and administrative work as it runs multiple complex drug programs with a small team. Anthropic said the resulting savings could allow the group to take on projects it otherwise could not pursue.
• Divergence Labs: The food allergy drug developer said it generated roughly 35,000 antibody designs in about a month. It identified three groups of designs that bound tightly to IgE and 20 that could help dislodge IgE from immune cells; three of the latter outperformed a standard medicine in that test. Divergence plans to combine the two types of components in a proposed drug design.

Geoff Harris, chief scientific officer and co-founder of Excellergy, challenged the significance of the Divergence findings. He argued that the study describes possible components rather than a drug and said other approaches to targeting IgE are further along. Excellergy’s candidate EXL-111 is a trifunctional treatment designed to act on the IgE pathway and is being studied in a Phase I trial. The disagreement underlines a useful distinction: early design and laboratory work can generate hypotheses, but comparisons with a clinical treatment require evidence from appropriately designed human studies.

Anthropic said it intends to extend Claude’s role as partner programs advance and to work with organizations whose drug candidates are already in clinical development. For now, the examples span very different tasks and stages. Their results should be assessed individually, with attention to whether they have been tested in people and whether they improve meaningful health outcomes.

Other notable company results

Acumen Pharmaceuticals fell 91%, from $2.29 to 21 cents, after its lead Alzheimer’s candidate, sabirnetug, failed to meet the main measure in the Phase II ALTITUDE-AD study. The trial compared the treatment with placebo in people with early Alzheimer’s disease. At 18 months, neither the 35 mg/kg nor the 50 mg/kg group showed a significant advantage on the Integrated Alzheimer’s Disease Rating Scale, which measures cognitive and functional decline. The study also did not show a statistically significant benefit on key secondary measures, including the Clinical Dementia Rating–Sum of Boxes, or a meaningful difference between treatment and placebo groups.

Acumen said it would stop developing sabirnetug, conserve cash and consider its options. The result is a reminder that promising biological targets and earlier development work do not guarantee a positive clinical trial.

Aspen Neuroscience shares ended their first full day of trading at $14.89, slightly below the $15 initial offering price, a decline of 0.7%. The company priced 9.375 million shares at the low end of its stated $15–$17 range, raising $140.625 million before expenses. It plans to use the proceeds to support clinical testing of sasineprocel, an autologous stem cell therapy for Parkinson’s disease, and development of programs involving microglia. Sasineprocel is in an open-label Phase I/IIa dose-escalation study; the company also plans studies needed before testing its microglia programs in people.

Genmab rose 28%, from $44.67 to $57.29, after reporting an interim analysis from the Phase III LiGeR-HN1 study. The trial compares petosemtamab plus pembrolizumab with pembrolizumab alone in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. An independent monitoring committee found a statistically significant improvement in overall survival, with a reported 50% reduction in the risk of death, as well as an improvement in objective response rate. The results met the trial’s two primary endpoints regardless of HPV status. They are an interim analysis; the full evidence and follow-up will matter when judging the size and durability of benefit.

Iovance Biotherapeutics dropped 35%, from $14.81 to $9.56, after sharing results from two groups in its Phase II study of lifileucel for previously treated metastatic non-small cell lung cancer. By the October 14 cutoff, 17 of 69 participants had responded, an objective response rate of 24.6%. That was close to the previously reported 25.6% among 39 participants, but below investor expectations. A retrospective analysis identified a subgroup defined by KRAS wild-type status, HER2 wild-type status and current or former smoking. Such an analysis can help guide further research, but it does not establish that the subgroup will benefit unless prospectively confirmed.

Across these updates, the most useful next evidence will come from larger and longer clinical studies, clearer follow-up on early responses, and the FDA’s final treatment of its proposed individualized framework. For patients and families, the research points to active development across several rare and serious conditions, while the therapies and approaches described remain at very different stages of testing.